In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus

Abstract

We investigated the in vitro activity of a new antifuingal triazole, D0870, against 100 Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus by using a broth macrodilution method following the recommendations provided by the National Committee for Clinical Laboratory Standards (document M27-P). All (4,8,10,21). No data are available about its in vitro activity against Candida albicans isolates from the oral cavities of human immunodeficiency virus (HIV)-infected patients. In the last few years the development of fluconazole-resistant isolates of C. albicans in these patients has been reported (3,5,11,15,19). The lack of standardized methods for in vitro antifungal susceptibility testing presents difficulties in recognizing isolates with reduced susceptibilities to the antifungal agents (12,13 (210) 567-4076. the oral cavities of HIV-infected patients were used in the study. Each strain represented a unique isolate from a patient. All of the strains were chosen from among C. albicans isolates already tested for fluconazole susceptibility by the NCCLS procedure (9). In order to obtain isolates of C. albicans with different patterns of in vitro susceptibility to fluconazole, we included 50 isolates for which the fluconazole MICs were s4 ,ug/ml, which were considered susceptible (group A), and 50 isolates for which the fluconazole MICs were .8 p,g/ml, which were considered resistant (group B) (Fig. 1). All of the isolates were tested for susceptibility to D0870 in a blind and random fashion by a broth macrodilution method following the recommendations provided by NCCLS (9). Two reference strains, C.

In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

“…We found that for isolates for which fluconazole MICs were high, voriconazole MICs were proportionally higher than those for non-fluconazole-resistant C. albicans isolates (MIC Ͻ 25 g/ml), which may indicate crossresistance. Barchiesi et al reported similar results for the triazoles itraconazole and D0870 against fluconazole-susceptible and -resistant C. albicans isolates in HIV-infected patients (1,2).…”

Antifungal susceptibility testing of yeast isolated from corneal infections

“…Recently, several studies have called attention to the occurrence of primary or acquired infections due to yeast resistant to antifungal drugs. Such reports are more frequent among patients with AIDS or malignant hematological diseases, situations in which the prophylactic or therapeutic use of antimycotics is more disseminated (28)(29)(30) The literature includes many studies which evaluate the susceptibility profile of yeast isolates from different biological fluids and tissues; however, none were found describing the antifungal susceptibility profile of yeast isolates from ocular infections (31)(32)(33)(34)(35) . Considering the high therapeutic failure rate associated with ocular fungal infections, the investigation of the antifun- gal susceptibility profile of ocular fungal pathogens may be useful to identify antifungal resistance as a possible risk factor for unfavorable outcome.…”

Heterogeneity of metallo and serine extracellular proteinases in oral clinical isolates ofCandida albicansin HIV-positive and healthy children from Rio de Janeiro, Brazil

“…These secreted proteinases were detected in the range of 30^95 kDa. Inspection of the gelatin gels revealed the presence of at least three (53, 58 and 95 kDa), ¢ve (64, 72, 76, 85 and 95 kDa), six (48, 53, 58, 64, 85 and 95 kDa) and seven (30,34,42,48, 53, 72 and 95 kDa) distinct proteolysis halos in acidic pH (5.5), in the A, B, C and D pattern, respectively (Fig. 1).…”

“…Moreover, mucosal candidiasis in AIDS patients is often difficult to treat and recurrences of the infections are frequent even after appropriate antifungal treatments, suggesting an increased potential of C. albicans to attack the debilitated host. Thus, it is likely that C. albicans participates actively in determining the nature of mucosal infection with its own virulence factors [42].…”